Last reviewed · How we verify
NCT04441489
Assessment of Lung Inflammation With FDG PET/CT in COVID-19
trial in COVID-19 in 13 participants. Completed in 27 May 2020.
3 May 2020
Quick facts
| Lead sponsor | Centre Hospitalier Princesse Grace |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 13 |
| Start date | 27 March 2020 |
| Primary completion | 3 May 2020 |
| Estimated completion | 27 May 2020 |
| Sites | 1 location across Monaco |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- FDG PET/CT — all drugs for FDG PET/CT →
- Inflammation — all drugs for Inflammation →
Sponsor
Centre Hospitalier Princesse Grace
Who can join
Adults 18 to 99, any sex, with COVID-19 or FDG PET/CT. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study was to assess the inflammatory status at the presumed peak of the inflammatory phase in non-critically ill patients requiring admission for COVID-19. Patients admitted with COVID-19 from March 27th to May 3rd, 2020 were prospectively enrolled. All patients had an initial chest CT-scan for diagnosis on admission and a second chest CT-scan for follow-up concomitant with a FDG PET/CT between day 6 and day 14 after the onset of symptoms.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome.
Dietz M, Chironi G, Claessens YE, Farhad RL, et al · · 2021 · cited 43× · PMID 32712702 · DOI 10.1007/s00259-020-04968-8
Verify or expand the search:
- PubMed search for NCT04441489
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Centre Hospitalier Princesse Grace trials
Trials by the same sponsor.
- NCT05885529 — Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1) to Exclude Lesions Linked to · recruiting
- NCT05779865 — Study of Different Gating Techniques for PET Image of Lung and Liver Lesions · completed
- NCT06131970 — The Effectiveness of Continuous Ketamine Infusion (KONTINUE) · completed
- NCT04437927 — Impact of 100mL Lipid Emulsion for Intravenous for Suppression of Myocardial Glucose Metabolism in 18F-FDG PET/CT · completed
- NCT04418193 — Patient Preference Trial for COVID-19 (PPT-COVID) · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04441489 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Princesse Grace
- Last refreshed: 22 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04441489.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing